Skip to content

CLINICAL RESEARCH ON SIDDHA MEDICINE IN IYA ERAIPPU NOI(BRONCHIAL ASTHMA)

EVALUATION OF SAFETY AND EFFICACY OF A POLY HERBAL FORMULATION ADATHODAI CHOORANAM IN IYA ERAIPPU NOI(BRONCHIAL ASTHMA)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/12/004253
Enrollment
125
Registered
2013-12-27
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- IYA ERAIPPU NOI(BRONCHIAL ASTHMA)

Interventions

Intervention1: ADATHODAI CHOORANAM: 1.5 gm of Adathodai chooranam will be administered along with milk twice a day orally for a period of 30 days. Control Intervention1: NIL: NIL

Sponsors

AYOTHIDOSS PANDITHAR HOSPITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who are having classical symptoms of Bronchial Asthma that difficulty in breathing, Tightness of Chest, Wheezing, Dry (or) Productive Cough, 2.Only new patients will be included. 3.Aged between 15 to 60 years of both sexes. 4.Willing to give blood specimen, sputum, Radiological Investigation and Willing to be admitted in the hospital (or) attend the OPD once a week for 3 weeks. 5.Patients who are willing to estimate volume of air forcibly expired after a deep inspiration by using peak flow meter

Exclusion criteria

Exclusion criteria: 1.Pregnancy and Lactation period. 2.Significant Systemic illness including Cardiac Diseases, Renal Diseases, Hypertension. 3.Patients with only nasal block or rhinorrhoea. 4.Other respiratory Diseases such as Tuberculosis, Pneumonia, COPD,Bronchiectasis, cystic fibroisis, 5.Endocrine Disorders like Hypo & Hyper Thyroidism, Diabetes Mellitus 6.Status Asthmaticus.

Design outcomes

Primary

MeasureTime frame
PEEK EXPIRATORY FLOW MEASUREMENT Outcome Good response Step4 Step1/Step2/Normal Step3 Step1/Step2/Normal Moderate response Step4 to Step3 no Significant Poor response Timepoint: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Secondary

MeasureTime frame
Eosinophils and ESR, AEC, Serum IgE level Pulmonary function tests, X-ray Chest Timepoint: PRE STUDY SCREENING AND AFTER 30 DAYS OF TREATMENT

Countries

India

Contacts

Public ContactDR THOMAS M WALTER

NATIONAL INSTITUTE OF SIDDHA

dr.kmvm@gmail.com9444979034

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026